A Next-Generation Approach to Sustainable Weight Loss

Harbour BioMed (HKEX: 02142) has announced the launch of Élancé Therapeutics, a biotechnology company dedicated to advancing next-generation obesity treatments. By leveraging cutting-edge bispecific antibody technology, Élancé aims to enhance weight loss outcomes while preserving muscle mass, addressing major gaps in existing obesity therapies.

The Challenge: Why Current Obesity Treatments Fall Short

Obesity affects nearly one billion people worldwide and is associated with serious health complications, yet current treatments have limitations, including:

Limited long-term efficacy – Many patients struggle with weight regain after treatment.
Loss of lean muscle mass – Existing weight loss therapies often reduce both fat and muscle, leading to undesirable outcomes.
Need for multi-pathway targeting – Current therapies primarily focus on single pathways, limiting their full potential.

How Élancé is Redefining Obesity Treatment

Élancé Therapeutics is developing a pipeline of bispecific antibody therapies designed to:

Enhance fat loss while preserving or increasing lean muscle mass
Improve metabolic regulation and long-term treatment efficacy
Target multiple pathways, including GLP-1, GIP, and GCG receptors
Leverage AI-driven drug discovery for optimized antibody design

A Powerful Technology Platform

Élancé will utilize Harbour BioMed’s HCAb-based bispecific antibody technology, which has been successfully applied in oncology and immunology. Additionally, it will refine and expand the Hu-mAtrIx™ AI platform, integrating machine learning to optimize antibody sequence discovery, bispecific geometry design, and patient biomarker analysis.

A Vision for the Future

According to Jingsong Wang, MD, PhD, Founder, Chairman, and CEO of Harbour BioMed:

“Our bispecific antibody programs enable a new paradigm in obesity treatment by targeting multiple pathways in a precise and effective manner. With a focus on optimizing weight loss efficacy, preserving lean muscle mass, and improving long-term outcomes, we believe our approach has the potential to redefine obesity therapeutics.”

The Road Ahead

Élancé’s preclinical pipeline is set to advance towards clinical trials, paving the way for a new era of biologic-based obesity treatments. With a focus on long-term health benefits, Élancé is positioned to complement existing treatments and transform the standard of care for obesity management.

Could this be the future of sustainable weight loss? With Élancé’s innovative approach, the industry is set for a major breakthrough in obesity treatment.